CYP2C19 metabolizes approximately 10-15% of all drugs, including clopidogrel, citalopram, diazepam, and many of the proton pump inhibitors. Detecting variants of the CYP2C19 gene that cause altered enzymatic activity can identify patients who may be at increased risk of having adverse drug reactions or therapeutic failure to standard dosages of CYP2C19 substrates.
Other variants of the CYP2C19 gene that are not detected in this assay may influence drug metabolism. CYP2C19 metabolic capacity is also influenced by concomitant medications, inhibitors, inducers, diet and various disease states. All factors should be considered as part of the overall patient management strategy.
Hybridization capture array technology with automated detection of multiplex PCR products or real-time polymerase chain reaction with fluorescence detection.
We provide the guidance needed for managing drug therapy for pain management. Genetic variations in drug-metabolizing enzymes have been shown to significantly affect patient response to various opioids, increasing the probability of overdose.